Meridian Wealth Advisors LLC Has $208,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Meridian Wealth Advisors LLC reduced its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 25.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,050 shares of the biopharmaceutical company’s stock after selling 1,400 shares during the quarter. Meridian Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $208,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. McClarren Financial Advisors Inc. increased its holdings in Bristol-Myers Squibb by 532.7% in the 4th quarter. McClarren Financial Advisors Inc. now owns 1,879 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,582 shares in the last quarter. Institute for Wealth Management LLC. raised its holdings in Bristol-Myers Squibb by 1.0% in the 4th quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company’s stock valued at $1,542,000 after buying an additional 296 shares during the last quarter. Herold Advisors Inc. boosted its position in Bristol-Myers Squibb by 3.2% during the 3rd quarter. Herold Advisors Inc. now owns 33,668 shares of the biopharmaceutical company’s stock worth $1,954,000 after buying an additional 1,051 shares during the period. Kestra Private Wealth Services LLC increased its position in Bristol-Myers Squibb by 9.5% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 139,811 shares of the biopharmaceutical company’s stock valued at $8,115,000 after acquiring an additional 12,121 shares during the period. Finally, Metis Global Partners LLC raised its stake in shares of Bristol-Myers Squibb by 14.8% during the third quarter. Metis Global Partners LLC now owns 101,772 shares of the biopharmaceutical company’s stock valued at $5,907,000 after acquiring an additional 13,122 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Price Performance

BMY traded down $0.37 during trading on Wednesday, reaching $43.67. 11,895,172 shares of the company were exchanged, compared to its average volume of 15,741,268. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The company has a market cap of $88.52 billion, a price-to-earnings ratio of -14.09, a P/E/G ratio of 14.82 and a beta of 0.45. Bristol-Myers Squibb has a 12-month low of $43.33 and a 12-month high of $69.10. The company’s 50-day moving average is $50.11 and its two-hundred day moving average is $50.48.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. During the same period in the previous year, the business earned $2.05 EPS. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. Research analysts forecast that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were issued a $0.60 dividend. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 5.50%. Bristol-Myers Squibb’s payout ratio is currently -77.42%.

Analyst Ratings Changes

A number of research firms recently weighed in on BMY. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. Barclays reduced their target price on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Finally, BMO Capital Markets lowered their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.